Literature DB >> 24367082

Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma.

Sara Mainardi1, Nieves Mijimolle, Sarah Francoz, Carolina Vicente-Dueñas, Isidro Sánchez-García, Mariano Barbacid.   

Abstract

Ubiquitous expression of a resident K-Ras(G12V) oncogene in adult mice revealed that most tissues are resistant to K-Ras oncogenic signals. Indeed, K-Ras(G12V) expression only induced overt tumors in lungs. To identify these transformation-permissive cells, we induced K-Ras(G12V) expression in a very limited number of adult lung cells (0.2%) and monitored their fate by X-Gal staining, a surrogate marker coexpressed with the K-Ras(G12V) oncoprotein. Four weeks later, 30% of these cells had proliferated to form small clusters. However, only SPC(+) alveolar type II (ATII) cells were able to form hyperplastic lesions, some of which progressed to adenomas and adenocarcinomas. In contrast, induction of K-Ras(G12V) expression in lung cells by intratracheal infection with adenoviral-Cre particles generated hyperplasias in all regions except the proximal airways. Bronchiolar and bronchioalveolar duct junction hyperplasias were primarily made of CC10(+) Clara cells. Some of them progressed to form benign adenomas. However, only alveolar hyperplasias, exclusively made up of SPC(+) ATII cells, progressed to yield malignant adenocarcinomas. Adenoviral infection induced inflammatory infiltrates primarily made of T and B cells. This inflammatory response was essential for the development of K-Ras(G12V)-driven bronchiolar hyperplasias and adenomas, but not for the generation of SPC(+) ATII lesions. Finally, activation of K-Ras(G12V) during embryonic development under the control of a Sca1 promoter yielded CC10(+), but not SPC(+), hyperplasias, and adenomas. These results, taken together, illustrate that different types of lung cells can generate benign lesions in response to K-Ras oncogenic signals. However, in adult mice, only SPC(+) ATII cells were able to yield malignant adenocarcinomas.

Entities:  

Keywords:  genetically engineered mouse model; inflammation; lung stem cells; non-small cell lung cancer

Mesh:

Substances:

Year:  2013        PMID: 24367082      PMCID: PMC3890787          DOI: 10.1073/pnas.1320383110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  18 in total

1.  Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras.

Authors:  E L Jackson; N Willis; K Mercer; R T Bronson; D Crowley; R Montoya; T Jacks; D A Tuveson
Journal:  Genes Dev       Date:  2001-12-15       Impact factor: 11.361

Review 2.  Epithelial progenitor cells in lung development, maintenance, repair, and disease.

Authors:  Jason R Rock; Brigid L M Hogan
Journal:  Annu Rev Cell Dev Biol       Date:  2011-05-31       Impact factor: 13.827

3.  Adenoviral augmentation of elafin protects the lung against acute injury mediated by activated neutrophils and bacterial infection.

Authors:  A J Simpson; W A Wallace; M E Marsden; J R Govan; D J Porteous; C Haslett; J M Sallenave
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

4.  The differential effects of mutant p53 alleles on advanced murine lung cancer.

Authors:  Erica L Jackson; Kenneth P Olive; David A Tuveson; Roderick Bronson; Denise Crowley; Michael Brown; Tyler Jacks
Journal:  Cancer Res       Date:  2005-11-15       Impact factor: 12.701

5.  Identification of tumorigenic cells in Kras(G12D)-induced lung adenocarcinoma.

Authors:  Huan-Chieh Cho; Chao-Yang Lai; Li-En Shao; John Yu
Journal:  Cancer Res       Date:  2011-11-16       Impact factor: 12.701

6.  Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma.

Authors:  Xia Xu; Jason R Rock; Yun Lu; Christopher Futtner; Brian Schwab; Justin Guinney; Brigid L M Hogan; Mark W Onaitis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-12       Impact factor: 11.205

7.  A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

Authors:  Marta Puyol; Alberto Martín; Pierre Dubus; Francisca Mulero; Pilar Pizcueta; Gulfaraz Khan; Carmen Guerra; David Santamaría; Mariano Barbacid
Journal:  Cancer Cell       Date:  2010-07-13       Impact factor: 31.743

8.  Atypical adenomatous hyperplasia and adenocarcinoma of the human lung: their heterology in form and analogy in immunohistochemical characteristics.

Authors:  M Mori; F Tezuka; R Chiba; Y Funae; M Watanabe; T Nukiwa; T Takahashi
Journal:  Cancer       Date:  1996-02-15       Impact factor: 6.860

9.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer.

Authors:  Simon A Forbes; Nidhi Bindal; Sally Bamford; Charlotte Cole; Chai Yin Kok; David Beare; Mingming Jia; Rebecca Shepherd; Kenric Leung; Andrew Menzies; Jon W Teague; Peter J Campbell; Michael R Stratton; P Andrew Futreal
Journal:  Nucleic Acids Res       Date:  2010-10-15       Impact factor: 16.971

10.  Alveolar type II cells possess the capability of initiating lung tumor development.

Authors:  Chuwen Lin; Hai Song; Cecilia Huang; Erica Yao; Rhodora Gacayan; Shan-Mei Xu; Pao-Tien Chuang
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

View more
  81 in total

1.  RUMI is a novel negative prognostic marker and therapeutic target in non-small-cell lung cancer.

Authors:  May Chammaa; Agnes Malysa; Carlos Redondo; Hyejeong Jang; Wei Chen; Gerold Bepler; Rodrigo Fernandez-Valdivia
Journal:  J Cell Physiol       Date:  2018-06-28       Impact factor: 6.384

Review 2.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Authors:  Matthew G Oser; Matthew J Niederst; Lecia V Sequist; Jeffrey A Engelman
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

3.  Transcription factor Etv5 is essential for the maintenance of alveolar type II cells.

Authors:  Zhen Zhang; Kim Newton; Sarah K Kummerfeld; Joshua Webster; Donald S Kirkpatrick; Lilian Phu; Jeffrey Eastham-Anderson; Jinfeng Liu; Wyne P Lee; Jiansheng Wu; Hong Li; Melissa R Junttila; Vishva M Dixit
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-28       Impact factor: 11.205

4.  Diverse cells at the origin of lung adenocarcinoma.

Authors:  Samuel P Rowbotham; Carla F Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2014-03-20       Impact factor: 11.205

Review 5.  Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

Review 6.  Lineage factors and differentiation states in lung cancer progression.

Authors:  W K C Cheung; D X Nguyen
Journal:  Oncogene       Date:  2015-03-30       Impact factor: 9.867

Review 7.  Are Gastric and Esophageal Metaplasia Relatives? The Case for Barrett's Stemming from SPEM.

Authors:  Ramon U Jin; Jason C Mills
Journal:  Dig Dis Sci       Date:  2018-08       Impact factor: 3.199

8.  TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.

Authors:  Nagako Akeno; Alisa L Reece; Melissa Callahan; Ashley L Miller; Rebecca G Kim; Diana He; Adam Lane; Jonathan S Moulton; Kathryn A Wikenheiser-Brokamp
Journal:  Mol Cancer Ther       Date:  2017-08-28       Impact factor: 6.261

9.  KRAS Allelic Imbalance Enhances Fitness and Modulates MAP Kinase Dependence in Cancer.

Authors:  Michael R Burgess; Eugene Hwang; Rana Mroue; Craig M Bielski; Anica M Wandler; Benjamin J Huang; Ari J Firestone; Amy Young; Jennifer A Lacap; Lisa Crocker; Saurabh Asthana; Elizabeth M Davis; Jin Xu; Keiko Akagi; Michelle M Le Beau; Qing Li; Benjamin Haley; David Stokoe; Deepak Sampath; Barry S Taylor; Marie Evangelista; Kevin Shannon
Journal:  Cell       Date:  2017-02-16       Impact factor: 41.582

10.  Protein Kinase Cι and Wnt/β-Catenin Signaling: Alternative Pathways to Kras/Trp53-Driven Lung Adenocarcinoma.

Authors:  Ning Yin; Yi Liu; Andras Khoor; Xue Wang; E Aubrey Thompson; Michael Leitges; Verline Justilien; Capella Weems; Nicole R Murray; Alan P Fields
Journal:  Cancer Cell       Date:  2019-08-01       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.